Gracell Bio - GRCL Net earnings per share for the last 12 months

Gracell (GRCL) - corporate logo

Gracell Biotechnologies (GRCL) is expanding its influence through innovative cryogenic logistics for CAR-T therapies. The 12-month EPS growth trend confirms the sustainability of the trajectory, with the current level sitting around 25.80. Financial security is guaranteed by a merger with a pharma behemoth, while technological progress is driven by leading experts in the field of gene editing.

gracellbio.com (GRCL): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

Financial and market metric breakdowns for Gracell Biotechnologies (GRCL)

Fundamental company valuation:GRCL Gracell Biotechnologies Inc.
Flagship merchandise of Gracell

Gracell Biotechnologies (GRCL) has been integrated into the structure of a global pharmaceutical behemoth to scale cell technologies. The dynamics of this merger directly impact the calculated earnings per share. This indicator measures the rolling annual EPS growth rate, bridging the gap between GAAP reporting and operating cash flow. It reveals fundamental resilience or signs of asset overheating. By analyzing the EPS YoY TTM growth value, an investor assesses the efficiency of the acquisition.